Bionano Genomics Q2 revenue rises on increased clinical adoption
BNGO•Outlook
- Bionano sees Q3 2026 revenue between $8.2 mln and $8.6 mln
- Company expects full-year 2026 revenue of $31 mln to $33 mln
- Growth expected to be driven by increased clinical adoption and utilization at clinical sites
Overview
- Genome analysis solutions provider's Q2 revenue rose 21% yr/yr to $8.2 mln
- Gross margin for Q2 improved to 53% from 52% a year earlier
- Company retired all outstanding secured convertible debentures, eliminating secured debt obligations
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
- Wall Street's median 12-month price target for Bionano Genomics, Inc. is $5.00, about above its August 7 closing price of
